Literature DB >> 27132582

Obesity and Hypogonadism.

Steven Lamm1, Aaron Chidakel2, Rohan Bansal2.   

Abstract

The relationship between obesity and hypogonadism is complicated. The relationship is bidirectional and there are numerous causative and correlative factors on both sides of the equation. Obesity is increasing in prevalence in epidemic proportions. Likewise, we are beginning to see the rapid increase in the incidence of male hypogonadism. It is only recently that we are learning the ways in which these 2 conditions exacerbate each other, and we are only beginning to understand how by treating one of these conditions, we can help to treat the other as well.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Hypogonadism; Obesity; Testosterone

Mesh:

Year:  2016        PMID: 27132582     DOI: 10.1016/j.ucl.2016.01.005

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  16 in total

Review 1.  Testosterone replacement therapy and cardiovascular disease.

Authors:  Jeremy M Auerbach; Mohit Khera
Journal:  Int J Impot Res       Date:  2022-01-09       Impact factor: 2.408

2.  Hypogonadal Men with Higher Body Mass Index have Higher Bone Density and Better Bone Quality but Reduced Muscle Density.

Authors:  Lina E Aguirre; Georgia Colleluori; Richard Dorin; David Robbins; Rui Chen; Bryan Jiang; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Calcif Tissue Int       Date:  2017-08-30       Impact factor: 4.333

3.  Is elevated body mass index protective against cervical spine injury in adults?

Authors:  Nicholas M Beckmann; Chunyan Cai; Susanna C Spence; Mark L Prasarn; O Clark West
Journal:  Emerg Radiol       Date:  2018-03-30

Review 4.  Metabolic regulation of kisspeptin - the link between energy balance and reproduction.

Authors:  Víctor M Navarro
Journal:  Nat Rev Endocrinol       Date:  2020-05-19       Impact factor: 43.330

Review 5.  Testosterone Replacement Therapy: Long-Term Safety and Efficacy.

Authors:  Giovanni Corona; Alessandra Sforza; Mario Maggi
Journal:  World J Mens Health       Date:  2017-04-30       Impact factor: 5.400

6.  Soy isoflavones improve the oxidative stress induced hypothalamic inflammation and apoptosis in high fat diet-induced obese male mice through PGC1-alpha pathway.

Authors:  Dejiang Pang; Chengcheng Yang; Qihui Luo; Chao Li; Wentao Liu; Lixia Li; Yuanfeng Zou; Bin Feng; Zhengli Chen; Chao Huang
Journal:  Aging (Albany NY)       Date:  2020-05-13       Impact factor: 5.682

Review 7.  Secondary male hypogonadism: A prevalent but overlooked comorbidity of obesity.

Authors:  MarIa Molina-Vega; Araceli Muñoz-Garach; Miguel Damas-Fuentes; José Carlos Fernández-García; Francisco J Tinahones
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

8.  Soy Isoflavones Improve the Spermatogenic Defects in Diet-Induced Obesity Rats through Nrf2/HO-1 Pathway.

Authors:  Qihui Luo; Yifan Li; Chao Huang; Dongjing Cheng; Wenjing Ma; Yu Xia; Wentao Liu; Zhengli Chen
Journal:  Molecules       Date:  2019-08-15       Impact factor: 4.411

9.  Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males.

Authors:  Alexander W Pastuszak; Mark Bush; Laura Curd; Saji Vijayan; Tony Priestley; Qinfang Xiang; Yiqun Hu
Journal:  J Clin Pharmacol       Date:  2021-09-12       Impact factor: 2.860

Review 10.  Testosterone deficiency in non-cancer opioid-treated patients.

Authors:  F Coluzzi; D Billeci; M Maggi; G Corona
Journal:  J Endocrinol Invest       Date:  2018-10-20       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.